Autolus Therapeutics plc (AUTL)

NASDAQ: AUTL · IEX Real-Time Price · USD
4.250
-0.100 (-2.30%)
Jul 19, 2024, 4:30 PM EDT - Market closed
-2.30%
Market Cap 1.13B
Revenue (ttm) 10.50M
Net Income (ttm) -221.26M
Shares Out 266.04M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 891,867
Open 4.330
Previous Close 4.350
Day's Range 4.200 - 4.360
52-Week Range 2.010 - 7.450
Beta 2.11
Analysts Strong Buy
Price Target 9.33 (+119.53%)
Earnings Date Aug 1, 2024

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell ly... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 22, 2018
Employees 463
Stock Exchange NASDAQ
Ticker Symbol AUTL
Full Company Profile

Financial Performance

In 2023, AUTL's revenue was $1.70 million, a decrease of -73.30% compared to the previous year's $6.36 million. Losses were -$208.38 million, 40.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 119.53% from the latest price.

Price Target
$9.33
(119.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

5 weeks ago - GlobeNewsWire

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent ste...

7 weeks ago - GlobeNewsWire

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial...

2 months ago - GlobeNewsWire

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t...

3 months ago - GlobeNewsWire

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

3 months ago - GlobeNewsWire

Autolus Therapeutics Announces Changes to its Board of Directors

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t...

3 months ago - GlobeNewsWire

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million upfront, plus underwritten offering of ADSs for $350 million, for gross proceeds of $600 mi...

4 months ago - GlobeNewsWire

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces t...

4 months ago - GlobeNewsWire

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

5 months ago - GlobeNewsWire

Autolus Announces Pricing of Underwritten Offering

LONDON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

5 months ago - GlobeNewsWire

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies' autologous CAR-T programs towards market, pending market authoriz...

5 months ago - GlobeNewsWire

Autolus Therapeutics announces publication in ACS Chemical Biology

LONDON, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a ...

6 months ago - GlobeNewsWire

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. 22, 2024 (GLOBE NEWS...

6 months ago - GlobeNewsWire

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic...

7 months ago - GlobeNewsWire

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) Company on track to submit a marketing ...

8 months ago - GlobeNewsWire

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II study, pooled analysis from ALLCAR19 and FELIX Phase Ib ...

8 months ago - GlobeNewsWire

Autolus Therapeutics announces participation in upcoming conferences

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces it...

9 months ago - GlobeNewsWire

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...

9 months ago - GlobeNewsWire

Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

9 months ago - GlobeNewsWire

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

10 months ago - GlobeNewsWire

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

10 months ago - GlobeNewsWire

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it...

1 year ago - GlobeNewsWire

Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer

- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program

1 year ago - GlobeNewsWire

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

1 year ago - GlobeNewsWire

Autolus Therapeutics announces publication in Cancer Immunology Research

LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a ...

1 year ago - GlobeNewsWire